about
Chapter 7: PharmacogenomicsHIV Treatment Adherence, Drug Resistance, Virologic Failure: Evolving ConceptsCo-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDSGenetic testing for prevention of severe drug-induced skin rashAbacavir-based triple nucleoside regimens for maintenance therapy in patients with HIVAbacavir versus other nucleoside reverse transcriptase inhibitor (NRTI) backbone therapies for treatment of HIV infectionA combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDSPeptide-binding motifs and characteristics for HLA -B*13:01 moleculeClinical use of pharmacogenomic tests in 2009In vitro Models to Evaluate Drug-Induced Hypersensitivity: Potential Test Based on Activation of Dendritic CellsMinION: A Novel Tool for Predicting Drug Hypersensitivity?T-cell-mediated drug hypersensitivity: immune mechanisms and their clinical relevanceGenetic Markers of the Host in Persons Living with HTLV-1, HIV and HCV InfectionsThe Need for Biomarkers in Diagnosis and Prognosis of Drug-Induced Liver Disease: Does Metabolomics Have Any Role?The 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected KoreansPharmacogenomics in the clinicAssessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicinePathogenesis and diagnosis of delayed-type drug hypersensitivity reactions, from bedside to bench and backImpact of New Genomic Technologies on Understanding Adverse Drug ReactionsPharmacogenetics as a tool to tailor antiretroviral therapy: A reviewReport from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.New approaches for predicting T cell-mediated drug reactions: A role for inducible and potentially preventable autoimmunityNew genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivityEvolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.Systems pharmacology: network analysis to identify multiscale mechanisms of drug actionIdiosyncratic adverse drug reactions: current conceptsPerspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbiditiesApplication of routine electronic health record databases for pharmacogenetic researchAbacavir pharmacogenetics--from initial reports to standard of carePharmacogenomics of adverse drug reactionsHarvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactomeDrug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoireFever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsSevere Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical ImplementationThe Importance of Patient-Specific Factors for Hepatic Drug Response and ToxicityProgress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicityPharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapyPharmacogenomics in diabetes mellitus: insights into drug action and drug discoveryTilting at quixotic trait loci (QTL): an evolutionary perspective on genetic causation
P2860
Q21563496-92A4A10D-E9BB-4FF9-92D7-C777B831FFFDQ22241321-BB20F631-F71D-477B-9F89-E93E5611677FQ24200188-1D4994E5-D1BC-426F-B7D5-DCF0899B8D0AQ24202114-DBC167AC-A391-4671-9B9F-5A7D4A0A7919Q24202180-96B3C898-3FB6-473F-B4C3-6A38E7BB2C06Q24235506-2A389481-78D6-4D36-B8B8-F93FDA13C70DQ24239831-93207C19-BFF2-4DD0-8F3B-A7711510C437Q24339559-104CB6B0-E7BB-4D70-A31F-2C1165D56176Q24657536-D0261271-C6CA-4C50-BEB9-A4A53AD29141Q26741420-71DB1614-E4DA-4A91-9AC7-0624958FD261Q26744637-6F79FFF8-A172-4CB9-8B8A-319F1C43C2EFQ26747638-8E525BC8-C6A2-4930-ABAF-418D73BDC6BFQ26768628-DE095DF0-9B4E-48F1-BF18-1C847BDCDDA0Q26772999-23081323-5E72-482B-86B7-0412087FF1B4Q26781379-9D8DF9D0-F3E0-40B8-89FB-B2DCA8575FECQ26782786-D15A7FA9-6070-4063-84FA-4261170A5952Q26783472-19D1D8BF-F2BE-49D0-96D0-C48EAF645EE5Q26784638-05D498C1-7D5A-40EC-810C-91D11B05E5BCQ26787099-E3EC851D-6860-4153-A4FE-562476ED18E9Q26797938-A8B4E3B4-7D47-4155-933F-F276D60B7FADQ26800964-BD98D369-3582-4982-888F-155C0B6FF2ABQ26800973-0D1122D2-DE13-4C62-9415-16084FBE9C1DQ26800976-9D09A331-9647-4CAF-8543-B312F99AA664Q26800980-72D0E379-A1C5-46A8-A8B6-5BC330AFC74AQ26824166-7498021D-28CD-4A6D-BDB8-6AB29B587EF0Q26824391-D5E65212-1359-4913-ACB0-072C57F033F0Q26853274-A9380027-8C54-4457-AF06-BE699C402BFFQ26864747-EA6D72EB-2BE4-4C73-9463-24BC8BA0B15EQ27008841-1AA58DC9-0149-437A-94E4-3AB8B91AC6CAQ27015820-15539AC9-AC23-4A7C-B578-38377864E55DQ27335598-ABDEB0DF-9BDE-400D-B70E-22ADBF867031Q27679355-97E0CB82-91FC-4A9E-AF4D-6372AE892575Q27692095-F56C11CA-3F81-41E6-A284-DD486A6E4982Q28069383-56A7FCF9-BD2B-40B0-A1B6-9662C3882418Q28076600-E99CB51C-8436-444D-941C-95F95FCC1D39Q28080256-ABCC4280-10BC-4EBA-8CB7-2AD7646C5CCDQ28083100-82B198FB-BB5C-4F84-9861-62CEBD3AECF5Q28083449-695258DA-B069-48D6-8249-EE1B4E4E6722Q28274686-89349ED8-F44C-40A8-9FF8-6ED7FBBDEB04Q28385221-E4260572-2382-49B2-8351-670125C48956
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
HLA-B*5701 screening for hypersensitivity to abacavir.
@ast
HLA-B*5701 screening for hypersensitivity to abacavir.
@en
HLA-B*5701 screening for hypersensitivity to abacavir.
@nl
type
label
HLA-B*5701 screening for hypersensitivity to abacavir.
@ast
HLA-B*5701 screening for hypersensitivity to abacavir.
@en
HLA-B*5701 screening for hypersensitivity to abacavir.
@nl
prefLabel
HLA-B*5701 screening for hypersensitivity to abacavir.
@ast
HLA-B*5701 screening for hypersensitivity to abacavir.
@en
HLA-B*5701 screening for hypersensitivity to abacavir.
@nl
P2093
P356
P1476
HLA-B*5701 screening for hypersensitivity to abacavir.
@en
P2093
Alastair Benbow
Arlene Hughes
Cassy Workman
Daren Thorborn
David Nolan
Eva Jägel-Guedes
Giampiero Carosi
Janez Tomazic
Jean-Michel Molina
Juan Flores Cid
P304
P356
10.1056/NEJMOA0706135
P407
P577
2008-02-01T00:00:00Z